Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 12

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 12
---
i) the market value of our common shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million.

<div align='center'>- 4 -

THE OFFERING</div>

This summary highlights information presented in greater detail elsewhere in this offering circular. This summary is not complete and does not contain all the information you should consider before investing in our securities. You should carefully read this entire offering circular before investing in our securities, including "Risk Factors" and our consolidated financial statements.

| Issuer               | Medicus Pharma Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Securities offered   | 1,490,000 Units on a “best efforts” basis, each Unit consisting of one of our common shares and one warrant to purchase one of our common shares. Each warrant will have an exercise price of $2.80 per share, will be exercisable immediately and will expire five years from the date of issuance. The Units will not be certificated or issued in stand‑alone form. The common shares and the warrants comprising the Units are immediately separable upon issuance and will be issued separately in this offering.                                                                              
 Pursuant to this offering circular, we are also offering 1,490,000 common shares issuable from time to time upon the exercise of the warrants offered hereby.                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Offering price       | $2.80 per Unit.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Common shares to be  
 outstanding          | 13,412,561 common shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Investor Suitability 
 Standards            | The Securities are being offered and sold to "qualified purchasers" (as defined in Regulation A under the Securities Act of 1933, as amended (the "Securities Act"). "Qualified purchasers" include any person to whom securities are offered or sold in a Tier 2 offering pursuant to Regulation A under the Securities Act.                                                                                                                                                                                                                                                                       |
| Use of Proceeds      | We intend to use the net proceeds from this offering to fund our Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using our doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use the net proceeds of this offering to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin